About: Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy
Creator	Wang, Xu Zhang, Li Sun, Chao He, Hua Ma, Kewei Li, ; Wang, ; Guo, Ye Qiu, Shi Xu, Yinghui Chao, ; Hua He, ; Kewei Ma, ; Qiu, Qing Shi Qiu, ; Sun, Mengyao
Source	Elsevier; Medline; PMC
abstract	Abstract Background Convalescent plasma (CP) has been used successfully to treat many types of infectious diseases, and it has shown initial effects in the treatment of the emerging 2019 coronavirus disease (COVID-19). However, its curative effect and feasibility have yet to be confirmed by formal evaluation and well-designed clinical trials. To explore the effectiveness of treatment and predict the potential effect of CP for COVID-19, studies of different types of infectious diseases treated with CP were included in this systematic review and meta-analysis. Methods Related studies were obtained from databases and screened based on the inclusion criteria. The data quality was assessed, and the data were extracted and pooled for analysis. Results We included 40 studies on CP treatment for infectious diseases We found that CP treatment could reduce the risk of mortality with a low incidence of adverse events, promote the production of antibodies, show the decline in viral load, and shorten the disease course. A meta-analysis of 15 controlled studies showed that there was a significantly lower mortality rate in the group treated with CP (pooled OR = 0.32, 95% CI: 0.19-0.52, P < 0.001, I2 = 54%) than in the control groups. Studies were mostly of low or very low quality with a moderate or high risk of bias. The sources of clinical and methodological heterogeneity were identified. The exclusion of heterogeneity indicated that the results were stable. Conclusions CP therapy has some curative effect and is well tolerated to treat infectious diseases. It is a potentially effective treatment for COVID-19.
has issue date	2020-07-04(xsd:dateTime)
bibo:doi	10.1016/j.ijid.2020.06.107
bibo:pmid	32634589
has license	els-covid
sha1sum (hex)	9af6846eeb6804830f7e5a4ddad2cff00f8b3891
schema:url	https://doi.org/10.1016/j.ijid.2020.06.107
resource representing a document's title	Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy
has PubMed Central identifier	PMC7334933
has PubMed identifier	32634589
schema:publication	Int J Infect Dis
resource representing a document's body	covid:9af6846eeb6804830f7e5a4ddad2cff00f8b3891#body_text
is schema:about of	named entity 'viral load' named entity 'meta-analysis' named entity 'antibodies' named entity 'risk' named entity 'Convalescent plasma therapy' named entity 'convalescent plasma therapy' named entity 'infectious diseases' named entity 'viral load' named entity 'clinical trial' named entity 'Ebola' named entity 'virus' named entity 'infusion' named entity 'viral load' named entity 'Cochrane Collaboration' named entity 'Ebola' named entity 'clinical symptoms' named entity 'control group' named entity 'antibodies' named entity 'virus' named entity 'SARS' named entity 'PCR' named entity 'specific immune response' named entity 'observational studies' named entity 'SARS-CoV' named entity 'meta-analysis' named entity 'H7N9' named entity 'virus' named entity 'transfuse' named entity 'significant difference' named entity 'virus' named entity 'diphtheria' named entity 'infectious diseases' named entity 'urogenital' named entity 'case report' named entity 'clinical trials' named entity '95% CI' named entity 'adverse events' named entity 'control group' named entity 'H5N1' named entity 'H5N1' named entity 'critical stage' named entity 'virus quantification' named entity 'adverse events' named entity 'controlled studies' named entity 'avian influenza' named entity 'transfusion' named entity 'antibodies' named entity 'symptom' named entity 'blood products' named entity 'jaundice' named entity 'infusion' named entity 'controlled study' named entity 'Clinical outcomes' named entity 'virus' named entity 'prospective study' named entity 'H1N1' named entity 'statistical heterogeneity' named entity 'March 30, 2020' named entity 'immune response' named entity 'significant difference' named entity 'H1N1' named entity 'tetanus' named entity 'CFR' named entity 'infection' named entity 'antibodies' named entity 'prospective studies'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software